During the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub spoke to Stefano Luminari, University of Modena and Reggio Emilia, Modena, IT. We asked, What is the role of treatment line and duration in patients with large B-cell lymphoma (LBCL) treated with chimeric antigen receptor (CAR) T cells?
First, Luminari highlights the improved outcomes shown with axicabtagene ciloleucel and lisocabtagene maraleucel when compared with standard therapies in the second-line setting, and the clinical implications of these results. He also discusses the impact of the earlier use of CAR T-cell therapy and the importance of identifying patients who have a high risk of relapse who may benefit from timely CAR T-cell therapy. He concludes that CAR T-cell therapy, particularly axicabtagene ciloleucel, represents a major advancement for patients with relapsed LBCL and raises the importance of detecting early signs of relapse.